GnRH agonists during chemotherapy should be offered as an option for ovarian function protection in premenopausal breast cancer patients receiving chemotherapy; however, limited evidence exists on their protective effect on the ovarian reserve and the potential for future pregnancies (Lambertini et al., 2015, 2018c).	STRONG ⊕⊕⊕⊕
In women with breast cancer, GnRH agonists during chemotherapy should not be considered an option for FP instead of cryopreservation techniques (Lambertini et al., 2015, 2018c).	STRONG ⊕⊕⊕◯
In malignancies other than breast cancer, GnRH agonists should not be routinely offered as an option for ovarian function protection and FP without discussion of the uncertainty about its benefit (Gilani et al., 2007; Senra et al., 2018).	STRONG ⊕◯◯◯
GnRH agonists during chemotherapy may be considered as an option for ovarian function protection in premenopausal patients with autoimmune diseases receiving cyclophosphamide. However, it should be acknowledged that limited data are available in this setting (Ben-Aharon et al., 2010; Marder et al., 2012; Brunner et al., 2015).	WEAK ⊕⊕◯◯
GnRH agonists should not be considered an equivalent or alternative option for FP but can be offered after cryopreservation techniques or when they are not possible.	GPP